Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported Operating Income of -$11.92 million for fiscal year 2025.
Shuttle Pharmaceuticals Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$11.92M | -54.8% |
| 2024 | -$7.70M | -30.6% |
| 2023 | -$5.89M | -130.7% |
| 2022 | -$2.55M | -46.5% |
| 2021 | -$1.74M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.27M | +25.7% | +42.0% |
| June 30, 2025 | -$3.91M | -163.7% | -32.5% |
| March 31, 2025 | -$2.95M | -113.1% | +3.3% |
| September 30, 2024 | -$3.05M | -90.8% | -105.8% |
| June 30, 2024 | -$1.48M | -1.2% | -7.1% |
| March 31, 2024 | -$1.38M | +10.4% | +13.4% |
| September 30, 2023 | -$1.60M | -94.7% | -9.1% |
| June 30, 2023 | -$1.47M | -314.5% | +5.1% |
- Shuttle Pharmaceuticals Holdings, Inc. showed a decrease of -54.8% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Shuttle Pharmaceuticals Holdings, Inc.’s operating income has declined by 583.7% (from -$1.74 million to -$11.92 million).
- The most recent figure is from Shuttle Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: